Plasmodium berghei K173: selection of resistance to naphthoquine in a mouse model

Exp Parasitol. 2011 Feb;127(2):436-9. doi: 10.1016/j.exppara.2010.08.020. Epub 2010 Sep 22.

Abstract

Naphthoquine (NQ), as a component of ARCO® which composed of NQ and artemisinin, is a new 4-aminoquinoline antimalarial synthesized by our institute. Here, a naphthoquine-resistant line of rodent malaria parasite was selected through exposing Plasmodium berghei Keyberg 173 strain to progressively increased drug pressure. The selected strain showed a more than 200-fold decreased susceptibility to NQ with a stable resistance phenotype after 10 serial passages without drug pressure or when cryopreserved over a period of 12 months. In a cross-resistance assay, the susceptibility of NQ-resistant parasites to chloroquine was decreased by 14.5-fold. These findings imply NQ-resistant parasites might be selected by long-term usage of NQ in epidemic areas and the efficacy of NQ or ARCO® in chloroquine-resistant Plasmodium falciparum epidemic areas should be monitored closely.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antimalarials / pharmacology*
  • Artemisinins / pharmacology*
  • Chloroquine / pharmacology
  • Dose-Response Relationship, Drug
  • Drug Resistance / physiology
  • Ethanolamines / pharmacology
  • Fluorenes / pharmacology
  • Lumefantrine
  • Malaria / drug therapy
  • Malaria / parasitology
  • Male
  • Mice
  • Naphthoquinones / pharmacology*
  • Plasmodium berghei / drug effects*
  • Pyrimethamine / pharmacology
  • Random Allocation

Substances

  • Antimalarials
  • Artemisinins
  • Ethanolamines
  • Fluorenes
  • Naphthoquinones
  • artemisinin-naphthoquine combination
  • Chloroquine
  • artemisinin
  • Lumefantrine
  • Pyrimethamine